CXLO is developing a minimally invasive treatment for an ectatic corneal disease that can bring early intervention to millions of patients globally. Their EpiSmart approach is a transformative cross-linking system designed to treat keratoconus without disrupting the epithelium, allowing for a rapid return to normal activities.CXLO was founded andis supported by experts in the field, including Michael W. Belin, MD, Chief Medical Officer, who developed the Belin ABCD Progression Display, which is able to identify keratoconus progression earlier than previously relied upon metrics.

Health & Wellness

Health Care

CXL Ophthalmics

Org chart

Similar companies